Guardant Health(GH) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $281 million, representing a 39% year-over-year growth, while full-year revenue reached $982 million, a 33% increase year-over-year [9][31] - Non-GAAP gross margin improved to 66% in Q4 2025, up from 63% in the prior year, driven by a significant reduction in Reveal cost per test [32] - Adjusted EBITDA loss improved to $64.9 million in Q4 2025, compared to $78.4 million in the prior year quarter [34] Business Line Data and Key Metrics Changes - Oncology revenue increased 30% to $190 million in Q4 2025, with oncology volumes growing 38% to approximately 79,000 tests [9][29] - Screening revenue totaled $35 million from approximately 38,000 Shield tests in Q4 2025, reflecting strong sequential growth [19][30] - Biopharma and data revenue grew 18% year-over-year to $210 million in 2025 [16][17] Market Data and Key Metrics Changes - Guardant360 Liquid volumes increased nearly 30%, supported by expanding clinical utility from SMART apps launched over the past year [30] - Reveal continued to be the fastest-growing oncology product, benefiting from CRC surveillance reimbursement and early uptake for late-stage therapy response monitoring [12][30] - Shield's adherence rate reached 93% across the first 100,000 tests ordered, significantly higher than other screening modalities [22] Company Strategy and Development Direction - The company aims to expand its multi-cancer detection capabilities with Shield, which now includes a multi-cancer detection result report [24] - Strategic collaborations with Quest Diagnostics and PathGroup are expected to broaden national reach and enhance commercial infrastructure [23] - The acquisition of MetaCyte Diagnostics is anticipated to enhance the oncology product portfolio and accelerate the multi-disease detection pipeline [28] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about continued strong growth in oncology, expecting 25%-27% revenue growth in 2026, supported by volume growth of approximately 30% [37] - The company anticipates free cash flow positive status for the core business in 2026, with a commitment to achieving company-wide cash flow breakeven by the end of 2027 [35][36] - Management highlighted the importance of reimbursement wins for therapy monitoring as a significant growth driver for the oncology business [46] Other Important Information - The company has established a robust pipeline of ongoing companion diagnostics programs, with 25 approvals to date across the U.S., Japan, and Europe [17] - The company expects to launch several new products in oncology, including Guardant360 Liquid CDx for lung FDA approval and Reveal Ultra [40] Q&A Session Summary Question: Can you elaborate on Reveal therapeutic monitoring and its opportunity? - Management expressed excitement about Reveal for therapy monitoring, emphasizing its synergy with Guardant360 for monitoring patient responses to therapies [44][46] Question: How should we think about the growth of oncology products throughout the year? - Management is bullish about 2026, expecting at least 20% growth in Guardant360 volumes and strong performance from Reveal [50][51] Question: What is the expected burn for Shield and the pacing of rep hiring in 2026? - The company anticipates a similar burn for screening as in 2025, around $220 million, while continuing to build out the commercial organization [54][56] Question: What is the latest thinking on ADLT pricing for Guardant360? - Management indicated that no ADLT pricing is baked into the 2026 guidance, with expectations for FDA submission in the second half of the year [60][61] Question: Can you discuss the opt-in rate for MCED Shield and potential FDA submission? - Management reported good adoption rates for the MCED offering, with enthusiasm from providers and patients, but did not disclose specific numbers [78]